Rituximab–bortezomib–dexamethasone induce high response rates in iMCD in clinical practice

Summary Treatment options for idiopathic multicentric Castleman disease (iMCD) are currently limited, especially for patients who do not respond or are resistant to interleukin‐6 inhibitors. For the first time, we innovatively designed a protocol using rituximab–bortezomib–dexamethasone (RVD) as first‐line consolidation therapy in patients newly diagnosed with iMCD. Furthermore, we adopted a no‐maintenance treatment strategy to simplify post‐remission care. Five patients with iMCD were enrolled (including one with TAFRO syndrome) and underwent the RVD regimen, all of whom achieved partial response (PR) or better. After four cycles of RVD, three (60%) patients achieved PR, while one (20%) achieved a complete response. These five patients, who achieved PR or better, discontinued treatment but remained stable for a median follow‐up of 11 months, with a duration of response of 7, 7, 10, 12 and 13 months, respectively. None of the patients experienced grade ≥3 adverse events during the observation period. Collectively, these findings demonstrated that the RVD regimen may be a promising treatment option for patients with iMCD. It was a safe and effective approach that resulted in lasting responses without the need for ongoing maintenance therapy.